Community-acquired pneumonia in casualty: Etiology, clinical features, diagnosis, and management (or a look at the "new" in pneumonia since 2002)

Current Opinion in Pulmonary Medicine

Volumn 10, Issue 3, 2004, Pages 166-170

  Alves, Donald W ^a,c   Kennedy, Matthew T ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c NONE   (United States)

Author keywords

Community acquired pneumonia; Diagnosis; Prevention; Treatment

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; KETOLIDE; LINEZOLID; MACROLIDE; OXAZOLIDINONE DERIVATIVE; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC APPROACH ROUTE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; MONOTHERAPY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION; VACCINATION;

EID: 1942535075     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200405000-00004     Document Type: Review

References (40)

1. Kamath A, Pasteur MC, Slade MG, et al.: Recognizing severe pneumonia with simple clinical and biochemical measurements. Clin Med 2003, 3:54-56. This study used four clinical markers to identify severe pneumonia (predicting death or intensive care).
2. Andrews J, Nadjm B, Gant V, et al.: Community-acquired pneumonia. Curr Opin Pulm Med 2003, 9:175-180. This is an excellent brief overview of agents, risk factors, testing, and treatment for CAP.
3. Merchant S, Mullins CD, Shih YT: Factors associated with hospitalization costs for patients with community-acquired pneumonia. Clin Ther 2003, 25:593-610. This article reviews average costs by risk group for CAP.
4. Ramirez JA: Community-acquired pneumonia in adults. Prim Care 2003, 30:155-171. This is a good general overview of risk stratification and treatment guidelines.
5. Pimentel LP, McPherson SJ: Community-acquired pneumonia in the emergency department: a practical approach to diagnosis and management. Emerg Med Clin North Am 2003, 21:395-420. The authors provide a very good review of history, microbiology, risk factors, and stratification as well as treatment guidelines and pitfalls for CAP.
6. Niederman MS, Ahmed QA: Community-acquired pneumonia in elderly patients. Clin Geriatr Med 2003, 19:101-120. This is a detailed review of geriatric physiologic changes increasing risk, symptom presentation, clinical identifiers for good/bad outcome, causes, treatment and timing, and vaccination.
7. Oosterheert JJ, Bonten MJ, Hak E, et al.: Severe community-acquired pneumonia: what's in a name? Curr Opin Infect Dis 2003, 16:153-159. This article compares society diagnostic criteria, reviews pathogens, risk factors, and treatment with summary tables of recent severe CAP studies, and encourages vaccination.
8. Brown RB, lannini P, Gross P, et al.: Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia - analysis of a hospital claims-made database. Chest 2003, 123:1503-1511. This article provides outcome information, found benefit to "routine" atypical coverage as well as dual antibiotic coverage versus monotherapy.
9. Arnold FW, Ramirez JA, McDonald LC, et al.: Hospitalization for community-acquired pneumonia: the Pneumonia Severity Index vs. clinical judgment. Chest 2003, 124:121-124. The poor positive predictive value of the Pneumonia Severity Index in the absence of consideration of clinical judgment is shown.
10. Barlow GD, Lamping DL, Davey PG, et al.: Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers. Lancet Infect Dis 2003, 3:478-488.
11. Drummond MF, Becker DL, Hux M, et al.: An economic evaluation of sequential IV/po moxifloxacin therapy compared to IV/po Co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003, 124:526-535. The authors found a reduction in cost and stay with guideline alternative treatment with fluoroquinolone.
12. Feldman RB, Rhew DC, Wong JY, et al.: Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 3-1/2 year experience from a Veterans Affairs hospital. Arch Intern Med 2003, 163:1718-1726. This study found monotherapy (at unspecified dose) was as effective as other American Thoracic Society regimens for mild to moderate inpatient CAP.
13. Campbell SG, Marrie TJ, Anstey R, et al.: The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003, 123:1142-1150. The authors found a low positive culture rate at substantial cost, with minimal contribution to care, usually in deference to physician judgment.
14. Lidman C, Burman LG, Lagergren A, et al.: Limited value of routine microbiological diagnostics in patients hospitalized for community-acquired pneumonia. Scand J Infect Dis 2002, 34:873-879. No significant contribution to management or outcome from determining the cause of CAP was found.
15. Kariuki S, Muyodi J, Mirza B, et al.: Antimicrobial susceptibility in community-acquired bacterial pneumonia in adults. East Afr Med J 2003, 80:213-217. The authors identify and express concern regarding high levels of drug-resistant pneumococci and influenzae.
16. Campbell SG, Marrie TJ, Anstey R, et al.: Utility of blood cultures in the management of adults with community acquired pneumonia discharged from the emergency department. Emerg Med J 2003, 20:521-523. Only six of 289 cultures had significant growth, with only two of 289 (0.69%) influencing treatment by culture result.
17. Cazzola M, Matera MG, Page CP: Novel approaches to the treatment of pneumonia. Trends Pharmacol Sci 2003, 24:306-314. Causes and new treatment directions are reviewed.
18. Mabie M, Wunderink RG: Use and limitations of clinical and radiologic diagnosis of pneumonia. Semin Respir Infect 2003, 18:72-79. The pitfalls of relying on clinical and radiographic diagnosis of CAP are reviewed.
19. Espana PP, Capelastegui A, Quintana JM, et al.: A prediction rule to identify allocation of inpatient care in community-acquired pneumonia. Eur Respir J 2003, 21:695-701. This study adds clinical factors to the Pneumonia Severity Index to support appropriate inpatient management of otherwise low-risk Pneumonia Severity Index patients.
20. Hagberg L, Carbon C, van Rensburg DJ, et al.: Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. Respir Med 2003, 97:625-633.
21. Garbino J, Sommer R, Gerber A, et al.: Prospective epidemiologic survey of patients with community-acquired pneumonia requiring hospitalization in Switzerland. Int J Infect Dis 2002, 6:288-293. This article reviews the demographics, diagnostic studies, microbiology, and limitations of testing in CAP.
22. Malcolm C, Marrie TJ: Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. Arch Intern Med 2003, 163:797-802. Factors influencing antibiotic choice for outpatients by evaluating clinicians are examined.
23. De Gaetano Donati K, Tumbarello M, Tacconelli E, et al.: Impact of highly active antiretroviral therapy (HAART) on the incidence of bacterial infections in HIV-infected subjects. J Chemother 2003, 15:60-65. This study identified reduced bacterial infections among an HIV-positive subset receiving aggressive antiretroviral therapy.
24. Jin Y, Carriere KC, Marrie TJ, et al.: The effects of community-acquired pneumonia during pregnancy ending with a live birth. Am J Obstet Gynecol 2003, 188:800-806. For age-matched pregnant/nonpregnant females with CAP, the disease is generally well tolerated if pregnancy concludes with livebirth.
25. Trends in COPD. Lung & Asthma Information Agency: Public Health Sciences Department, St. George's Hospital Medical School, London. Fact sheet, 2003/1. The World Health Organization estimates the chronic obstructive pulmonary disease prevalence will increase from the 12th to the fifth chronic disease worldwide by 2020, indicating substantial an increase in a high-risk patient population.
26. Lim WS, Van der Eerden MM, Laing R, et al.: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382. These authors provide and validate a simple four-or five-component severity score against CAP mortality risk.
27. Menendez R, Perpina M, Torres A: Evaluation of nonresolving and progressive pneumonia. Semin Respir Infect 2003, 18:103-111. This article discusses considering culturing only if more severe presentation on admission or failure within first 72 hours.
28. Fernandez-Sabe N, Carratala J, Dorca J, et al.: Efficacy and safety of sequential amoxicillin-clavulanate in the treatment of anaerobic lung infections. Eur J Clin Microbiol Infect Dis 2003, 22:185-187.
29. Golden WE, Brown P, Godsey N: CMS releases new standards for community acquired pneumonia. J Ark Med Soc 2003, 99:288-289. This article identifies new US Centers for Medicare and Medicaid Services standards, national performance measures, and empiric antibiotic recommendations for CAP.
30. Shah MN, Schmit J, Croley WC, et al.: Continuity of antibiotic therapy in patients admitted from the emergency department. Ann Emerg Med 2003, 42:117-123. Substantial delays in the continuation of antibiotic treatment from the emergency department were shown.
31. Drugs for Pneumonia: treatment guidelines. Med Lett 2003, 1:83-88. This is an excellent brief overview of CAP pathogens, ambulatory versus hospitalized treatment options, and average costs and side effects.
32. Sanchez F, Mensa J, Martinez JA, et al.: Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? Clin Infect Dis 2003, 36:1239-1245. This study found shorter inpatient stay and reduced mortality with 3-day course of azithromycin versus a 10-day course of clarithromycin.
33. Correa JC, Badaro R, Bumroongkit C, et al.: Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV cephtriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Clin Ther 2003, 25:1453-1468.
34. Blasi F, Tarsia P, Cosentini R, et al.: Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections. Expert Opin Investig Drugs 2003, 12:1165-1177. This article highlights the efficacy and cost-effectiveness with caution against over-use.
35. Anderson KB, Tan JS, File TM Jr, et al.: Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003, 37:376-381. This study identifies a transient fluoroquinolone resistance in immunocompromised patients after successful fluoroquinolone treatment of CAP.
36. Telithromycin: a needless addition to the other macrolides. Prescrire Int 2003, 12:8-11. Side effect profile includes risk of torsades de pointes and visual symptoms plus P-450 inhibition without clear benefit over currently available alternatives.
37. Wilcox MH: Efficacy of linezolid versus comparator therapies in gram-positive infections. J Antimicrob Chemother 2003, 51 (suppl 2): ii27-ii35. This article reviews efficacy trials for this new oxazolidinone antibiotic.
38. Linezolid in severe gram-positive infections. Prescrire Int 2003, 12:46-48. This article voices concern regarding overutilization risk and monoamine oxidase inhibitor effect with risk of interaction.
39. Jackson LA, Neuzil KM, Yu O, et al.: Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003, 348:1747-1755. This study supports vaccination benefits, even with a sicker subset in a vaccination group.
40. Letters to the editor: N Engl J Med 2003, 349:712-716.